CA2902965C - Inorganic nitrite to improve cardiopulmonary hemodynamics - Google Patents

Inorganic nitrite to improve cardiopulmonary hemodynamics Download PDF

Info

Publication number
CA2902965C
CA2902965C CA2902965A CA2902965A CA2902965C CA 2902965 C CA2902965 C CA 2902965C CA 2902965 A CA2902965 A CA 2902965A CA 2902965 A CA2902965 A CA 2902965A CA 2902965 C CA2902965 C CA 2902965C
Authority
CA
Canada
Prior art keywords
nitrite
use according
dose
pulmonary
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2902965A
Other languages
English (en)
French (fr)
Other versions
CA2902965A1 (en
Inventor
Mark Thomas Gladwin
Hunter Clay Champion
Edwin PARSLEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of CA2902965A1 publication Critical patent/CA2902965A1/en
Application granted granted Critical
Publication of CA2902965C publication Critical patent/CA2902965C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2902965A 2013-02-28 2014-02-28 Inorganic nitrite to improve cardiopulmonary hemodynamics Active CA2902965C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361771063P 2013-02-28 2013-02-28
US61/771,063 2013-02-28
PCT/US2014/019703 WO2014134585A1 (en) 2013-02-28 2014-02-28 Inorganic nitrite to improve cardiopulmonary hemodynamics

Publications (2)

Publication Number Publication Date
CA2902965A1 CA2902965A1 (en) 2014-09-04
CA2902965C true CA2902965C (en) 2023-08-29

Family

ID=51428880

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2902965A Active CA2902965C (en) 2013-02-28 2014-02-28 Inorganic nitrite to improve cardiopulmonary hemodynamics

Country Status (5)

Country Link
US (3) US20160008394A1 (cg-RX-API-DMAC7.html)
EP (1) EP2961479A4 (cg-RX-API-DMAC7.html)
JP (3) JP6531990B2 (cg-RX-API-DMAC7.html)
CA (1) CA2902965C (cg-RX-API-DMAC7.html)
WO (1) WO2014134585A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE372777T1 (de) 2003-07-09 2007-09-15 Us Gov Health & Human Serv Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen
CA2900526C (en) * 2013-02-07 2021-05-04 The Trustees Of The University Of Pennsylvania Compositions and their use to treat heart failure with preserved injection fraction (hfpef)
US20160008394A1 (en) * 2013-02-28 2016-01-14 Aires Pharmaceuticals, Inc. Inorganic nitrite to improve cardiopulmonary hemodynamics
US11083704B2 (en) * 2017-01-03 2021-08-10 Bristol-Myers Squibb Company Method of administering nitroxyl donating compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4509515A (en) 1982-02-23 1985-04-09 Fisons Plc Inhalation device
US4889116A (en) 1987-11-17 1989-12-26 Phospho Energetics, Inc. Adaptive control of neonatal fractional inspired oxygen
DE69127756T2 (de) 1990-12-05 1998-02-05 The General Hospital Corp., Charlestown, Mass. Verwendung von no zur behandlung oder prävention der bronchokonstriktion
US5427797A (en) 1993-04-06 1995-06-27 Brigham And Women's Hospital Systemic effects of nitric oxide inhalation
AU5939901A (en) * 2000-10-27 2002-05-06 Nitromed Inc Methods of treating vascular diseases characterized by nitric oxide insufficiency
ATE372777T1 (de) * 2003-07-09 2007-09-15 Us Gov Health & Human Serv Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen
JP2010519335A (ja) 2007-02-26 2010-06-03 ルンドベルク，ヨン 運動能力向上組成物及びその使用
JP2010519336A (ja) 2007-02-26 2010-06-03 ルンドベルク，ヨン 亜硝酸塩及び硝酸塩及びこれらを含む組成物の新規使用
WO2009029836A2 (en) * 2007-08-31 2009-03-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitrite and nitrite-metheme therapy to detoxify stroma-free hemoglobin based blood substitutes
WO2011056572A1 (en) 2009-10-27 2011-05-12 The Board Of Trustees Of The University Of Illinois Methods of diagnosing diastolic dysfunction
GB201020811D0 (en) * 2010-12-08 2011-01-19 Solvotrin Innovations Ltd Compounds
US20140112983A1 (en) * 2011-04-14 2014-04-24 Theravasc Inc. Nitrite compositions and uses thereof
WO2013116194A2 (en) * 2012-01-30 2013-08-08 O'connell Timothy D Method of treating or limiting development of heart failure with preserved ejection fraction and tissue fibrosis
CA2900526C (en) * 2013-02-07 2021-05-04 The Trustees Of The University Of Pennsylvania Compositions and their use to treat heart failure with preserved injection fraction (hfpef)
US20160008394A1 (en) * 2013-02-28 2016-01-14 Aires Pharmaceuticals, Inc. Inorganic nitrite to improve cardiopulmonary hemodynamics

Also Published As

Publication number Publication date
CA2902965A1 (en) 2014-09-04
US20180360873A1 (en) 2018-12-20
EP2961479A1 (en) 2016-01-06
JP2016510040A (ja) 2016-04-04
US11219640B2 (en) 2022-01-11
US20160008394A1 (en) 2016-01-14
WO2014134585A1 (en) 2014-09-04
JP2022121544A (ja) 2022-08-19
US20220088065A1 (en) 2022-03-24
JP2019123754A (ja) 2019-07-25
EP2961479A4 (en) 2017-07-05
US11986493B2 (en) 2024-05-21
JP6531990B2 (ja) 2019-06-19

Similar Documents

Publication Publication Date Title
US11986493B2 (en) Inorganic nitrite to improve cardiopulmonary hemodynamics
Dixon et al. Bradykinin‐induced bronchoconstriction: inhibition by nedocromil sodium and sodium cromoglycate.
Defilippis et al. End-tidal arterial CO2 partial pressure gradient in patients with severe hypercapnia undergoing noninvasive ventilation
Duke et al. Decreased arterial, not O2 content, increases blood flow through intrapulmonary arteriovenous anastomoses at rest
Srichana et al. Evaluation of proinflammatory cytokines and adverse events in healthy volunteers upon inhalation of antituberculosis drugs
Manara et al. Lactic acidosis following intentional overdose by inhalation of salmeterol and fluticasone
El-Kersh et al. Pulmonary hypertension inhaled therapies: an updated review
Kokturk et al. A randomized clinical trial of magnesium sulphate as a vehicle for nebulized salbutamol in the treatment of moderate to severe asthma attacks
Weinstein et al. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 [micro] g and 400/10 [micro] g combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids
US11925625B2 (en) Methods of treating chemical gas exposure
Sriboonyong et al. Efficacy and safety of inhaled nebulized sodium nitrite in asthmatic patients
Navanandan et al. Positive expiratory pressure for the treatment of acute asthma exacerbations: a randomized controlled trial
Leemans et al. Functional response to inhaled salbutamol and/or ipratropium bromide in Ascaris suum-sensitised cats with allergen-induced bronchospasms
Terzano et al. Beclomethasone dipropionate versus budesonide inhalation suspension in children with mild to moderate persistent asthma
Drollmann et al. Effect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteers
Harrison et al. Comparison of wet and dry aerosol salbutamol
Lapin et al. Outpatient management of acute exacerbations of asthma in children
Hendeles et al. Response to nonprescription epinephrine inhaler during nocturnal asthma
Shah et al. Severe COVID-19 case with HRCT score of 25/25: A survival story
Nabi et al. A pharmacological comparative study of arformoterol and salbutamol nebulization in the management of patients suffering from acute non-severe bronchial asthma
Baldock Chronic Lung Conditions and Smoking at Altitude
KR20240033039A (ko) 호흡기 질환의 치료
Tuladhar et al. Determining Efficacy of Salbutamol in Restrictive Spirometry
Duke et al. Decreased arterial.
Rajakulasingam et al. Interactive effect of inhaled bradykinin with histamine and PGD2 in bronchial asthma

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190228

EEER Examination request

Effective date: 20190228

EEER Examination request

Effective date: 20190228

EEER Examination request

Effective date: 20190228

EEER Examination request

Effective date: 20190228

EEER Examination request

Effective date: 20190228

EEER Examination request

Effective date: 20190228